Abstract Exportin 1 (XPO1), also known as chromosome region maintenance protein 1,
plays a crucial role in maintaining cellular homeostasis via the regulated export of a range of …

Multiple myeloma (MM) is a plasma cell neoplasm that accounts for 2% of all haematological
malignancies and predominantly affects older individuals (with a median age at diagnosis of …

PURPOSE CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of
ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory …

Background CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene
autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation …

Background Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-
cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of …

Background Selinexor, a selective inhibitor of nuclear export compound that blocks exportin
1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins …

Cellular homeostasis requires the proper nuclear-cytoplasmic partitioning of large
molecules, which is often deregulated in cancer. XPO1 is an export receptor responsible for …

Simple Summary Hematological malignancies are diseases involving the abnormal
production of blood cells. The aim of the study is to collect comprehensive information on …

Selinexor is an oral inhibitor of the nuclear export protein exportin 1. Preclinical studies
demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors …

Central to eukaryotic cell function, transport into and out of the nucleus is largely mediated
by members of the Importin (IMP) superfamily of transporters of α-and β-types. The first …